Posts By: Jamie Crosno

“The management of locally advanced #RectalCancer has grown in both complexity and quality since the first proctectomy. What once was a malignancy with a fairly consistent treatment algorithm for decades, a recent paradigm shift in the care of these patients has led to a more personalized, multidisciplinary approach with variations in timing, sequence, duration, and potential exclusion… Read more »

Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses the potential utility of trifluridine/tipiracil (TAS-102; Lonsurf) in combination with bevacizumab (Avastin) in metastatic colorectal cancer (mCRC). Currently, TAS-102 is reserved for single-agent use in the third-line setting for patients with mCRC, says Grothey. However, TAS-102… Read more »

Join Dr. Axel Grothey, our Director of GI Cancer Research, on Thursday, May 20 at 7pm ET as he co-hosts an OncLive webinar titled “The Impact of Minimal Residual Disease in Cancer” alongside Tanois Behaii-Saab, MD and Manju George, MVSc PhD. Click here to learn more or register for this event: https://globalmeet.webcasts.com/starthere.jsp…

Saturday, March 20, 2021 8 a.m.–1:30 p.m. CDT Organizers: Axel Grothey, MD– West Cancer Center & Research Institute Lee S. Schwartzberg, MD, FACP– West Cancer Center & Research Institute  ACI Memphis Program Registration Registration is for the program is NOW OPEN. You must be registered to attend the program. Program Agenda March 20, Program The program is hosted… Read more »

West Cancer Center has modeled research driven, patient centered oncology care for over 40 years with a reputation for educating and advancing cancer treatments in the Midsouth, Nationally and Internationally. Their 6th Annual West Oncology Conference, usually held at the Guest house at Graceland, was held virtually on February 26 with a distinguished panel of… Read more »

Abstract The phosphatidylinositol-3-kinase (PI3K) pathway is frequently dysregulated in human breast cancer. Approximately 30%of all patients with breast cancer will carry mutations of the PIK3CA gene, which encodes the PI3K catalytic subunit isoform p110a. Mutations in PIK3CA have been associated with resistance to endocrine therapy, HER2-directed therapy, and cytotoxic therapy. Early trials of pan-PI3K inhibitors… Read more »